Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses due in part to development of experimental ...

THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in ...

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Now, biopharmaceutical company Amgen has been developing a new weight loss drug called MariTide-and early trials are showing big results. Here's everything you need to know about the new GLP-1 ...

Amgen in November said MariTide helped patients with obesity lose up to 20% of their weight on average after a year in a phase two trial, with no weight loss plateau. The drug also helped patients ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic ...

--Amgen today announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the ...

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market.